Floatz logo

Deferasirox

Iron Poisoning

Novartis PharmaceuticalsSmall moleculePhase 4 / ApprovedDormant
A
82/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Iron Poisoning cohort.

Asset / SponsorPhaseRating
Deferiprone
Ain Shams University
Phase 3BB
Deferitazole
Shire
Phase 2B
DESFERRIOXAMINE B
Ain Shams University
Phase 2B
Defearisox Film-Coated
Novartis Pharmaceuticals
Phase 2B
10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one
Horus University
D
Ferriprox
Ain Shams University
N/AD

Same molecule, other indications

Deferasirox is also rated in:

hemosiderosisDormant
A
Indicative ·
81 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
79 / 100
View asset →
iron metabolism diseaseDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →